Valion Bio, Inc. VBIO
Valion Bio, Inc. (Nasdaq: VBIO) is a drug developer. Its lead program, Entolimod, is in Phase 1 for Acute radiation syndrome.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Entolimod (TLR5 agonist) | Acute radiation syndrome (Animal Rule) | protein/peptide | Phase 1 |
| Entolimod | Neutropenia | protein/peptide | Pre-clinical |
| Entolasta | Undisclosed | protein/peptide | Pre-clinical |
Recent results and decisions
- Oct 22, 2026n/a Valion is working with Sheba Medical Center towards a clinical trial evaluating Entolimod in cancer patients receiving high doses of irradiation.
Valion is working with Sheba Medical Center towards a clinical trial evaluating Entolimod in cancer patients receiving high doses of irradiation, representing another potential development pathway.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.